Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 284 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1When should genetic testing be performed in patients with neuroendocrine tumours?
Triona O’Shea,Maralyn Druce
Reviews in Endocrine and Metabolic Disorders.2017;18(4)499
[DOI]
2Clonidine suppression testing for pheochromocytoma in neurofibromatosis type 1
WingYee Wan,Bichle Nguyen,Sky Graybill,Jonathan Kim
BMJ Case Reports.2019;12(6)e228263
[DOI]
3‘Adrenal rush’ in a patient with Neurofibromatosis-1
Samiha Khan,Beenish Fayyaz,Janki Patel
Journal of Community Hospital Internal Medicine Perspectives.2020;10(3)250
[DOI]
4Synchronous detection of SDHA-related gallbladder paraganglioma and pancreatic neuroendocrine tumor
Trine Aaquist,Jesper Bondo Medhus,Anders Thomassen,Sönke Detlefsen
Pathology - Research and Practice.2020;216(7)153006
[DOI]
5Ophthalmic clues to the endocrine disorders
Z. Liu,Y. Chen,Z. Lin,X. Shi
Journal of Endocrinological Investigation.2017;40(1)21
[DOI]
6Combination chemotherapy regimen in a patient with metastatic malignant pheochromocytoma and neurofibromatosis type 1
Zenia Nahleh
American Journal of Case Reports.2014;15(1)123
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal